Related Experiment Video
Updated: Sep 17, 2025

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis
Tarek Aboursheid1, Azizullah Beran2, Mohamad Hijazi3
1Department of Internal Medicine, Saint Francis Hospital, Evanston, Illinois.
Background And Aims:
Anti-tumor necrosis factor therapy has been a mainstay of medical management of perianal Crohn's disease (CD). This systematic review and meta-analysis aimed to compare the efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of perianal fistulizing CD.
Methods:
We searched PubMed, Embase, and Web of Science databases for studies that compared the efficacy of ADA with IFX for treatment of patients with perianal fistulizing CD. Single-arm studies were excluded. The primary outcomes were perianal CD healing evaluated clinically or radiologically.
Results:
Six observational studies with a total of 590 patients with perianal CD (216 received ADA and 374 received IFX) were included. Overall, perianal CD healing was comparable between ADA and IFX (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.76-1.06, P = .20). Subgroup analysis based on the healing assessment method showed no significant difference between ADA and IFX whether assessment was performed clinically (RR 0.90, 95% CI 0.67-1.21, P = .49) or radiologically (RR 0.91, 95% CI 0.74-1.13, P = .40).
Conclusion:
In this systematic review and meta-analysis, ADA was not inferior to IFX in effectiveness for the treatment of perianal CD. Head-to-head prospective and randomized controlled studies comparing ADA and IFX are necessary to validate the findings of this study.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...